Tesamorelin

Tesamorelin is a synthetic analogue of human GHRH consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus. It is studied in research for its stabilized GHRH receptor agonist activity and effects on GH secretion dynamics and somatotroph signaling.

Tesamorelin is a stabilized synthetic analogue of human GHRH (1-44) with an N-terminal trans-3-hexenoic acid modification. It is studied in research for its enhanced GHRH receptor agonism and GH secretion dynamics. Supplied as a lyophilized research peptide.

Tesamorelin was developed by Theratechnologies as a stabilized GHRH analogue. The trans-3-hexenoic acid modification was engineered to reduce enzymatic degradation at the N-terminus while preserving full GHRH receptor agonist activity. Published research has characterized its enhanced pharmacokinetic profile compared to native GHRH.

Published studies demonstrate that Tesamorelin activates the GHRH receptor with potency comparable to native GHRH, stimulating cAMP-dependent GH secretion from pituitary somatotrophs. Its N-terminal modification confers resistance to dipeptidyl peptidase-IV (DPP-IV) degradation, extending its bioactive duration in research models. Studies have characterized its GH pulsatility effects and IGF-1 axis modulation.